Phase Ⅱ Study of HAIC of FOLFOX vs. Sorafenib in HCC Refractory to TACE

Hepatocellular Carcinoma Clinical Trial

Official title:

Randomized Phase Ⅱ Study of Second-line Treatment Comparing Hepatic Arterial Infusion Chemotherapy of Oxaliplatin, 5-fluorouracil and Leucovorin With Sorafenib in Hepatocellular Carcinoma Refractory to Transarterial Chemoembolization

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT03722498
• Other study ID #: HCC-H171011
• Status: Withdrawn
• Phase: Phase 2
• Start date: June 1, 2018
• Est. completion date: March 22, 2021

Study information

• Verified date: July 2023
• Source: Sun Yat-sen University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To evaluate safety and efficacy of combined hepatic arterial infusion chemotherapy (HAIC) of oxaliplatin, 5-fluorouracil and leucovorin and sorafenib in hepatocellular carcinoma (HCC) refractory to transarterial chemoembolization(TACE)

Description:

In most current guidelines, sorafenib is considered as the second-line treatment for patients with transarterial chemoembolization(TACE) failure or refractoriness.However,the median overall survival of those treated with sorafenib monotherapy was 16.4 to 24.7 months.

Whether combining sorafenib with hepatic arterial infusion chemotherapy(HAIC) of oxaliplatin,5-fluorouracil and leucovorin is safe, well tolerated, and efficacious remains unknown, with no prospective clinical data currently available.The investigators therefore conducted a prospective and randomized phase II trial to compare the safety and efficacy of HAIC with sorafenib in patients refractory to TACE

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: March 22, 2021
• Est. primary completion date: March 22, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• TACE failure or refractoriness based on the Liver Cancer Study Group of Japan (LCSGJ) criteria, including appearance of vascular invasion or two or more consecutive insufficient responses of the intrahepatic lesion;

• Except for TACE, patients have received no previous anti-tumor treatment;

• The diagnosis of HCC was based on histological results;

• Patients must have at least one tumor lesion that can be accurately measured;

• Not amendable to surgical resection ,local ablative therapy and any other cured treatment;

• No Cirrhosis or cirrhotic status of Child-Pugh class A only;

• No liver protection therapy in 2 weeks before enrolled, and meet the following laboratory parameters:(a) Platelet count = 75,000/µL; (b)Hemoglobin = 8.5 g/dL;(c) Total bilirubin = 30mmol/L;(d) Serum albumin = 32 g/L;(e) ASL and AST = 5 x upper limit of normal;(f) Serum creatinine = 1.5 x upper limit of normal;(g) INR > 2.3 or PT/APTT within normal limits; (h) Absolute neutrophil count (ANC) >1,500/mm3;

• Ability to understand the protocol and to agree to and sign a written informed consent document

Exclusion Criteria:

• Evidence of hepatic decompensation including ascites, gastrointestinal bleeding or hepatic encephalopathy;

• Known history of HIV;

• History of organ allograft;

• Known or suspected allergy to the investigational agents or any agent given in association with this trial;

• Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy;

• Any other hemorrhage/bleeding event > CTCAE Grade 3 within 4 weeks of first dose of study drug.

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Hepatocellular
• Hepatocellular Carcinoma

Intervention

Drug:
• HAIC of FOLFOX
administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
• Sorafenib
administration of Sorafenib

Locations

Country	Name	City	State
China	Guangzhou Twelfth People 's Hospital	Guangzhou	Guangdong
China	Ming Shi	Guangzhou	Guangdong
China	Kaiping Central Hospital	Kaiping	Guangdong

Sponsors (3)

Lead Sponsor	Collaborator
Sun Yat-sen University	Guangzhou No.12 People's Hospital, Kaiping Central Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression-free survival	The period from the date of the start of HAIC or sorafenib until the date of the confirmation of tumor progression or death	12 months
Secondary	Overall survival	The period from the date of the start of HAIC or sorafenib until the date of the confirmation of tumor progression or death	12 months
Secondary	Adverse Events	Postoperative adverse events were graded based on CTCAE v4.03	30 Days after HAIC and TACE
Secondary	Objective response rate	Best response based on mRECIST	12 months